Overview

Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Alberta Health Services

Collaborators:

CancerCare Manitoba
Jewish General Hospital
Newfoundland Cancer Treatment & Research Foundation
Notre-dame Hospital
Ottawa Hospital Research Institute

Treatments:

Pilocarpine